PRIMARY STUDY
Gut barrier and microbiota changes with glycine and branched-chain amino acid supplementation in chronic haemodialysis patients
Key Findings: This study looked at the effects of amino acids on the gut microbiome relating to the administration of branched-chain amino acids (BCAA) and glycine supplements for patients undergoing hemodialysis. There was no difference between BCAA and glycerin on cytokines, appetite, gut permeability, endocannabinoids, or fecal levels of immunoglobulin A.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 27
Study Result: Negative
Research Location(s): Switzerland
Year of Pub: 2021
Cannabinoids Studied: Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG), Endocannabinoid (unspecified), Other Related Compounds, Palmitoylethanolamide (PEA), Microbiome
Phytocannabinoid Source: Not Applicable
Ligands Studied: Ghrelin, Glucagon, Leptin, Pro-inflammatory cytokines
Route of Administration: Endogenous
Citation: Genton L, et al. Gut barrier and microbiota changes with glycine and branched-chain amino acid supplementation in chronic haemodialysis patients. J Cachexia Sarcopenia Muscle. 2021; 12:1527-1539. doi: 10.1002/jcsm.12781
Authors: Genton L, Pruijm M, Teta D, Bassi I, Cani PD, Gaïa N, Herrmann FR, Marangon N, Mareschal J, Muccioli GG, Stoermann C, Suriano F, Wurzner-Ghajarzadeh A, Lazarevic V, Schrenzel J
